Learning from TARDIS: time for more focused trials in stroke prevention

1Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Antithrombotic therapy immediately following stroke is important to minimise the risk of recurrence, but the optimum choice and number of drugs to use are unclear, and efficacy in preventing thrombosis needs to be weighed against bleeding risk. In The Lancet, the TARDIS investigators report findings from a randomised trial1 that tested intensive antiplatelet therapy with three agents (aspirin, clopidogrel, and dipyridamole) against therapy based on current UK guidelines2 (either clopidogrel, or aspirin plus dipyridamole) for 30 days in patients with transient ischaemic attack (TIA) or ischaemic stroke.

Cite

CITATION STYLE

APA

Amarenco, P. (2018, March 3). Learning from TARDIS: time for more focused trials in stroke prevention. The Lancet. Lancet Publishing Group. https://doi.org/10.1016/S0140-6736(17)33309-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free